Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00130871

Enrollment

Registered

2005-08-16

Start date

2004-01-31

Completion date

2006-01-31

Last updated

2007-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

levosimendan, weaning, cardio-pulmonary bypass

Brief summary

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Detailed description

Levosimendan or placebo infusion is started at the time of induction of anesthesia.

Interventions

DRUGlevosimendan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Three vessel coronary artery disease. * Indication for on-pump coronary artery bypass surgery. * Ejection fraction below 50%

Exclusion criteria

* Indication for any cardiac valve surgery * Previous coronary artery bypass surgery

Design outcomes

Primary

Measure	Time frame
Proportion of successful primary weanings	—

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026